Cue Biopharma, Inc. (CUE)
Nasdaq · Healthcare · Biotechnology
$24.36−4.73%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $177M
- 52-week range
- $4.98 – $45.50
- 52-week change
- +13.34%
- EPS (trailing)
- −$29.59
- Analyst rating
- 1.0 Strong buy
Fiscal year to Dec 2025
- Revenue
- $27.5M (+195.75%)
- Net income
- −$26.6M
- Operating margin
- −96.7%
- Diluted EPS
- −$0.28
- Free cash flow
- −$21.9M
From the company’s annual report on SEC EDGAR.
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Headquarters: Boston, United States · 29 employees · cuebiopharma.com